Skip to main content
Premium Trial:

Request an Annual Quote

IP Update: Feb 5, 2009


Title: Markers for Diagnosis of Cancer and Its Use

Number: 20090028863

Filed: Sept.12, 2006 PCT Filed: Sept. 12, 2006

Lead Inventor: In Kyung Shin, Daewoong

The patent application, its abstract states, claims CTHRC1, CANP, and KIAA0101 as diagnostic biomarkers that are over-expressed in breast or colorectal cancer. It also claims “a method for diagnosing the cancer by detecting the markers, and a method for preventing or treating by inhibiting the expression and activity of the markers” using RNAi.

Title: Method on Clinical Applications in Head and Neck Cancer by Using DSG3 Molecule for Predicting Malignant Degree of Cancer, Serving as a Molecular Target, and Using RNA Jamming Sequence on Inhibition Specific of DSG3 Expression

Number: 20090029354

Filed: Nov. 6, 2006

Lead Inventor: Joseph Tung-Chieh Chang, Chang Gung University

The invention comprises “a method for analyzing the DSG3 over-expression in tumor tissues with clinical features of cancer cells to validate that DSG3 over-expression … relates to size, depth, and migration of tumor,” the patent application’s abstract states.

“DSG3 over-expression is capable for using in clinical applications, determining malignant degree of tumor, serving as molecular target in head [and] neck cancer,” it adds. “Moreover, a jamming sequence, RNA, is designed to act on DSG3 mRNA and is effective [to inhibit] DSG3 expression, [which in turn] inhibits cell growth, invasion, and migration in HNC.”

The application specifically claims an RNAi sequence that targets DSG3 mRNA.

Title: Methods and Compositions for the Specific Inhibition of Gene Expression by Double-Stranded RNA

Numbers: 20090029466, 20090029936

Filed: June 20, 2008

Lead Inventor: John Rossi, City of Hope (Integrated DNA Technologies)

“The invention,” the patent application’s abstract states, “is directed to compositions and methods for selectively reducing the expression of a gene product from a desired target gene in a cell, as well as for treating diseases caused by the expression of the gene. More particularly, the invention is directed to compositions that contain double-stranded RNA, and methods for preparing them, that are capable of reducing the expression of target genes in eukaryotic cells.”

Specifically, the abstract states, “the dsRNA has a first oligonucleotide sequence that is between 25 and about 30 nucleotides in length and a second oligonucleotide sequence that anneals to the first sequence under biological conditions. In addition, a region of one of the sequences of the dsRNA having a sequence length of at least 19 nucleotides is sufficiently complementary to a nucleotide sequence of the RNA produced from the target gene to trigger the destruction of the target RNA by the RNAi machinery.”

Title: Identification and Use of miRNAs for Differentiating Myeloid Leukemia Cells

Number: 20090029932

Filed: May 3, 2007

Lead Inventor:
Olivier Voinnet, Centre National De La Recherche Scientifique

“The invention relates to the use of nucleic acid miRNA derived molecules for producing a drug for treating a myelogenous leukemia and to a method for identifying therapeutic agents or the efficient combination thereof for inducing the differentiation of myelogenous leukemia cells,” the patent application’s abstract states.

Title: RNA Interference in Respiratory Epithelial Cells

Number: 20090029934

Filed: Oct. 16, 2007

Lead Inventor: Paul McCray, University of Iowa

According to the patent application’s abstract, the invention is “directed to small interfering RNA molecules targeted against a gene of interest in respiratory epithelial cells, and methods of using these RNA molecules.”

Title: siRNA Targeting 1-Acylglycerol-3-Phosphate O-Acyltransferase 2


July 27, 2007

Lead Inventor:
Anastasia Khvorova, Dharmacon (Thermo Fisher Scientific)

“Efficient sequence-specific gene silencing is possible through the use of siRNA technology,” the patent application’s abstract states. “By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene-silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to AGPAT2.”